Form 4: Revolution Medicines' COO Margaret Horn Executes Stock Option Plan, Sells Shares

Margaret Horn, Chief Operating Officer of Revolution Medicines, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 11 and 12, 2024, Margaret Horn, the Chief Operating Officer of Revolution Medicines, executed transactions involving the company's common stock.
• These transactions involved the exercise of stock options and the subsequent sale of shares.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on March 29, 2023.
• On March 11, 2024, Horn exercised options to acquire 15,735 shares at a price of $4.09 per share and then sold those shares at a weighted average price of $34.0201.
• On March 12, 2024, Horn exercised options to acquire 7,936 shares at a price of $4.09 per share and then sold those shares at a weighted average price of $34.0657.
• Following these transactions, Horn directly owns 142,467 shares of common stock and holds options to purchase 44,631 additional shares.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock option exercises and sales by an executive, executed under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often governed by pre-arranged trading plans like the 10b5-1 plan to avoid accusations of insider trading. These transactions can be viewed by investors as a signal, though often they are part of a planned diversification or liquidity strategy for the executive.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a significant component, aligning executive interests with shareholder value.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage the sale of company stock while mitigating insider trading concerns.
• Comparing the exercise price and sale price to industry peers would require analyzing similar transactions at comparable biotech companies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Key Dates